USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

NewsGuard 100/100 Score
Sep 2 2010

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules.

These generic atomoxetine hydrochloride capsules are equivalent to Eli Lilly's Strattera ® capsules and include six strengths: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, and 100 mg.

Annual sale in US for these strengths of branded and generic atomoxetine hydrochloride capsules is estimated at over $ 530 million.

Atomoxetine Hydrochloride capsules are indicated for the management of attention deficit hyperactivity disorder in children aged 6 and older,teens and adults.

Source:

 Sun Pharma

Posted in: Child Health News | Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Study highlights global fertility decline and its implications for the future
LabVantage celebrates customer success with record number of software deployments in FY 2024
Common HIV drugs linked to reduced Alzheimer's disease risk
Study reveals ADHD medication reduces psychiatric hospitalizations and work disability
New urine-based test improves identification of high-grade prostate cancer
Supply chain assessment and management, optimizing pharmaceutical supply chains
Lancet Commission predicts sharp increase in global prostate cancer cases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients